title: T-cell/histiocyte-rich large B-cell lymphomas and classical diffuse large B-cell lymphomas have similar outcome after chemotherapy: a matched-control analysis.
abstract: OBJECTIVE
  Because it is unclear whether T-cell/histiocyte-rich large B-cell lymphomas (H/TCRBCL) should be considered as a true clinicopathologic entity, we conducted a matched-control analysis comparing patients with H/TCRBCL and patients with diffuse large-B cell lymphoma (B-DLCL).
  
  
  METHODS
  More than 4,500 patients were enrolled onto non-Hodgkin's lymphoma trials conducted by the Groupe d'Etude des Lymphomes de l'Adulte. After histologic review, 50 patients were subclassified as H/TCRBCL. They were matched to 150 patients with B-DLCL for each of the factors of the International Prognostic Index (IPI).
  
  
  RESULTS
  Clinical characteristics of H/TCRBCL patients showed a male predominance and a median age of 47 years. Performance status was normal in 89% of patients, whereas lactate dehydrogenase level was increased in 60% of patients. The disease was disseminated in 81% of patients, and 48% had two or more involved extranodal sites. The IPI score was >or= 2 in 53% of patients. The complete response rate to chemotherapy was 63%, and 5-year overall survival (OS) and event-free survival (EFS) rates (mean +/- SD) were 58% +/- 18% and 53% +/- 16%, respectively. The matched-control analysis showed a trend toward a better response to chemotherapy for patients with B-DLCL (P =.06), whereas no difference was observed in OS (P =.9) and EFS (P =.8).
  
  
  CONCLUSIONS
  H/TCRBCL is an aggressive disease that often presents with adverse prognostic factors. However, when treatment is adapted to the disease risk, outcome is equivalent to that observed in patients with B-DLCL. Thus H/TCRBCL should be considered a pathologic variant that belongs to the B-DLCL category.
authors.affiliation: Cancer Center Institut Paoli-Calmettes-Université de la Méditerranée, Marseille. hemato1@marseille.fnclcc.fr
authors.forename: R
authors.initials: R
authors.lastname: Bouabdallah
authors.forename: N
authors.initials: N
authors.lastname: Mounier
authors.forename: C
authors.initials: C
authors.lastname: Guettier
authors.forename: T
authors.initials: T
authors.lastname: Molina
authors.forename: V
authors.initials: V
authors.lastname: Ribrag
authors.forename: C
authors.initials: C
authors.lastname: Thieblemont
authors.forename: A
authors.initials: A
authors.lastname: Sonet
authors.forename: A
authors.initials: A
authors.lastname: Delmer
authors.forename: K
authors.initials: K
authors.lastname: Belhadj
authors.forename: P
authors.initials: P
authors.lastname: Gaulard
authors.forename: C
authors.initials: C
authors.lastname: Gisselbrecht
authors.forename: L
authors.initials: L
authors.lastname: Xerri
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006644:Histiocytes / Q000473:pathology*; D006801:Humans; D016393:Lymphoma, B-Cell / Q000145:classification* / Q000188:drug therapy / Q000401:mortality; D016403:Lymphoma, Large B-Cell, Diffuse / Q000145:classification* / Q000188:drug therapy / Q000401:mortality; D008297:Male; D016555:Matched-Pair Analysis; D008875:Middle Aged; D011379:Prognosis; D015996:Survival Rate; D013601:T-Lymphocytes / Q000473:pathology*; D016896:Treatment Outcome